Globe Newswire
Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences
Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences 5 January 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will participate in a fireside chat at two upcoming investor conferences, details of which can be found below: H.C. Wainwright BioConnect 2021 Conference Date: January 11, 2021Time: 6:00 a.m. EST (13:00 GMT) ICR Conference 2021 Date: Thursday, January 14, 2021Time: 8:30- 9:10 a.m. EST (13:30 - 14:10 GMT) Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at https://ift.tt/38gf6vS. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference. Enquiries: Silence Therapeutics plcGem Hopkins, Head of IR and Corporate Communicationsir@silence-therapeutics.com Tel: +1 (646) 637-3208 Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence Tel: +44 (0) 20 7597 5970European IRConsilium Strategic CommunicationsMary-Jane Elliott/ Angela Gray / Chris Welshsilencetherapeutics@consilium-comms.com Tel: +44 (0) 20 3709 5700U.S. IRWestwickePeter Vozzopeter.vozzo@westwicke.com Tel: +1 (443) 213-0505 About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://ift.tt/2SKksHj
"asian" - Google News
January 05, 2021 at 05:58PM
https://ift.tt/3q3d5t1
Top Mobile Payment Service Providers in Select Asian Countries - Amid the COVID-19 Pandemic, Asian Consumers Prefer Local M-PSPs - Yahoo Finance UK
"asian" - Google News
https://ift.tt/2STmru2
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
No comments:
Post a Comment